Implications of a Circulating Vaccine-Derived Poliovirus in Nigeria
| Autor: | Michael Mwanza, Alex Gasasira, Nicholas C. Grassly, Emmanuel Abanida, Christl A. Donnelly, Muhammad Pate, F.D. Adu, Helen E. Jenkins, Marycelin Baba, Jukka Corander, R. Bruce Aylward, Sandra Garnier, Claire Chauvin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
0303 health sciences
medicine.medical_specialty 030306 microbiology business.industry Poliovirus Outbreak General Medicine medicine.disease_cause medicine.disease Virology Virus 3. Good health Poliomyelitis Vaccination 03 medical and health sciences 0302 clinical medicine Epidemiology Paralysis Medicine Enterovirus 030212 general & internal medicine medicine.symptom business |
| Zdroj: | New England Journal of Medicine |
| ISSN: | 0028-4793 |
| DOI: | 10.1056/NEJMx100064 |
| Popis: | Background The largest recorded outbreak of a circulating vaccine-derived poliovirus (cVDPV), detected in Nigeria, provides a unique opportunity to analyze the pathogenicity of the virus, the clinical severity of the disease, and the effectiveness of control measures for cVDPVs as compared with wild-type poliovirus (WPV). Methods We identified cases of acute flaccid paralysis associated with fecal excretion of type 2 cVDPV, type 1 WPV, or type 3 WPV reported in Nigeria through routine surveillance from January 1, 2005, through June 30, 2009. The clinical characteristics of these cases, the clinical attack rates for each virus, and the effectiveness of oral polio vaccines in preventing paralysis from each virus were compared. Results No significant differences were found in the clinical severity of paralysis among the 278 cases of type 2 cVDPV, the 2323 cases of type 1 WPV, and the 1059 cases of type 3 WPV. The estimated average annual clinical attack rates of type 1 WPV, type 2 cVDPV, and type 3 WPV per 1... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|